# Organon

> Organon is a global pharmaceutical company focused on women’s health, with contraception and fertility products alongside biosimilars and established medicines. Created by Merck’s 2021 spinoff, it reported $6.216 billion in 2025 revenue. Sun Pharma agreed to acquire it in April 2026; the transaction is expected to close in early 2027, subject to remaining conditions.

- **Founded:** 2021
- **Headquarters:** Jersey City, United States
- **Founders:** Kevin Ali (Founding CEO of the independent company, 2021-2025)
- **Products:** NEXPLANON, NuvaRing, FOLLISTIM AQ / Puregon, HADLIMA, VTAMA
- **Notable:** Became an independent NYSE-listed company on June 3, 2021, under ticker OGN., Built a portfolio of over 70 products across more than 140 markets, according to 2026 company disclosures., Secured a U.S. five-year NEXPLANON indication in January 2026.

## Products & services

- **NEXPLANON** — Etonogestrel contraceptive implant; U.S. approved duration extended to five years in January 2026. Requires trained providers and a U.S. REMS program.
- **NuvaRing** — Prescription etonogestrel/ethinyl estradiol contraceptive vaginal ring.
- **FOLLISTIM AQ / Puregon** — Follitropin beta fertility medicines; branding and availability vary by market.
- **HADLIMA** — Adalimumab biosimilar to Humira, developed and manufactured by Samsung Bioepis and commercialized by Organon in licensed markets.
- **VTAMA** — Tapinarof cream, 1%, acquired through Dermavant in 2024; U.S. indications include plaque psoriasis in adults and atopic dermatitis in adults and children aged two and older.
- **MIUDELLA** — Hormone-free copper IUD exclusively licensed globally from Sebela in June 2026. U.S. approved for up to three years; a six-year extension is under FDA review.
- **Established medicines** — Portfolio across cardiovascular, respiratory, dermatology, bone health and other therapeutic areas, including brands such as Singulair and Fosamax.
- **Biosimilar commercialization** — Portfolio includes Renflexis, Ontruzant and Tofidence, with availability and rights varying by country.

## Achievements

- Became an independent NYSE-listed company on June 3, 2021, under ticker OGN.
- Built a portfolio of over 70 products across more than 140 markets, according to 2026 company disclosures.
- Secured a U.S. five-year NEXPLANON indication in January 2026.
- Named to Fortune’s 2023 Change the World list for expanding access to contraception.
- Completed the Dermavant acquisition in October 2024, adding VTAMA.

## Latest updates

- **2026-10** — October 16: announced interim Phase 3 MIUDELLA data through six years; the approved U.S. duration remains three years and an extension is under FDA review.
- **2026-10** — October 1: announced plans to present real-world VTAMA effectiveness analysis at the Fall Clinical Dermatology Conference.
- **2026-07** — Organon shareholders approved the Sun Pharma merger on July 23; Sun Pharma acknowledged approval July 24.
- **2026-06** — Completed the exclusive global licensing agreement for MIUDELLA with Sebela on June 22.
- **2026-04** — Announced agreement for Sun Pharma to acquire Organon for $14 per share in cash, at an $11.75 billion enterprise valuation.
- **2026-01** — Completed the JADA sale to Laborie on January 28, after agreeing to $440 million at closing plus up to $25 million in contingent consideration.

## Links

- Website: https://www.organon.com/
- LinkedIn: https://www.linkedin.com/company/organon/
- Twitter/X: https://twitter.com/OrganonLLC
- YouTube: https://www.youtube.com/channel/UCFXZcWljXuEhDkMCmZZ4Yzw
- Instagram: https://www.instagram.com/organonllc/
- Facebook: https://www.facebook.com/OrganonLLC
- TikTok: https://www.tiktok.com/@organon_llc

---

Profile page: https://yespress.io/organon
Published by YesPress — https://yespress.io
Last updated: 2026-10-22